Alpha Teknova, Inc. TKNO

Healthcare SIC 2835 - In Vitro & In Vivo Diagnostic Substances NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Alpha Teknova, Inc. (referred to herein as the Company, Teknova, we, us or our) is a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Our more than 3,000 customers span the continuum of the life sciences market and include leading pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions. Our Company is built around our knowledge, methods, and know-how in our manufacturing processes and infrastructure, which are highly adaptable and configurable. These proprietary processes enable us to manufacture and deliver high-quality, custom, made-to-order products with short turnaround times and at scale, across all stages of our customers' product development, including commercialization.

Last close 6.42 2026-10-23
Market cap $344.7M 2026-06-30 share count
52-week range 1.91 - 9.48

Valuation FY2025 figures against the last close

P/S8.5x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.32

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • United States
  • Non-US
Revenue by geography, 2 categories over 2 years. The same figures are in the table below. FY2025 United States, FY2025: 38.2M (94.4%) 94% United States Non-US, FY2025: 2.3M (5.6%) 6% Non-US FY2024 United States, FY2024: 35.9M (95.2%) 95% Non-US, FY2024: 1.8M (4.8%) 5%
Region FY2025FY2024
United States $38.2M $35.9M
Non-US $2.3M $1.8M

As the company reported it, from the “Revenue Recognition - Disaggregation of Revenue (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue $40.5M$37.7M$36.7M$41.4M$36.9M$31.3M—
Cost of revenue $27.1M$30.5M$26.4M$23.9M$19.3M$13.5M—
Gross profit $13.4M$7.2M$10.3M$17.5M$17.6M$17.8M—
R&D $2.2M$2.8M$5.6M$7.7M$4.3M$1.5M—
SG&A $20.3M$23.1M$25.4M$28.3M$20.4M$8.2M—
Total operating expenses $30.4M$33.4M$45.9M$67.1M$29.6M$13.1M—
Operating income -$17.0M-$26.1M-$35.6M-$49.7M-$12.0M$4.7M—
Interest expense $710.0K$687.0K$833.0K$213.0K$589.0K$87.0K—
Pre-tax income -$17.2M-$26.8M-$37.1M-$49.4M-$12.6M$4.7M—
Income tax $58.0K$88.0K$298.0K$1.9M$2.8M$1.2M—
Net income -$17.3M-$26.7M-$36.8M-$47.5M-$9.8M$3.6M—
EPS, basic -0.32-0.57-1.16-1.69-0.610.17—
EPS, diluted -0.32-0.57-1.16-1.69-0.610.16—
Shares, diluted (wtd. avg.) 53.5M46.7M31.8M28.1M16.1M3.8M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents $5.9M$3.7M$28.5M$42.2M$87.5M$3.3M$4.1M
Short-term investments $15.4M$26.7M$0—$0$1.8M—
Receivables $4.6M$4.3M$3.9M$4.3M$4.7M$4.6M—
Inventory $7.1M$6.8M$11.6M$12.2M$5.4M$3.6M—
Total current assets $34.5M$42.8M$45.7M$61.1M$101.2M$16.4M—
Property, plant and equipment $41.7M$45.8M$50.4M$51.6M$29.8M$10.0M—
Goodwill ———$0$16.6M$16.6M—
Other intangibles $11.9M$13.1M$14.2M$17.6M$18.7M$19.9M—
Total assets $103.6M$118.8M$128.6M$152.3M$166.5M$62.9M—
Accounts payable $1.4M$825.0K$1.5M$2.4M$2.2M$1.6M—
Short-term debt $0$4.0M$0————
Total current liabilities $7.5M$11.2M$8.9M$10.9M$7.7M$4.0M—
Long-term debt $13.1M$9.4M$13.3M$22.0M$11.9M$0—
Total liabilities $34.8M$36.4M$38.6M$52.4M$23.3M$10.5M—
Retained earnings -$135.8M-$118.5M-$91.8M-$55.0M-$7.5M$2.3M—
Total equity $68.8M$82.4M$90.0M$99.9M$143.2M$16.8M$12.9M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating cash flow -$8.6M-$12.4M-$18.8M-$27.4M-$9.1M$2.5M—
Depreciation and amortisation $6.3M$6.6M$5.7M$4.5M$2.9M$2.0M—
Stock-based compensation $3.4M$3.7M$4.1M$3.7M$1.6M$300.0K—
Capital expenditure $1.1M$1.1M$7.9M$28.1M$19.9M$5.5M—
Investing cash flow $10.7M-$27.3M-$7.7M-$28.1M-$17.5M-$1.7M—
Financing cash flow $151.0K$14.9M$12.8M$10.3M$110.8M-$1.6M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001850902-26-000002.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -50M -25M 0 25M 50M Revenue, FY2020: 31.3M Gross profit, FY2020: 17.8M Net income, FY2020: 3.6M Revenue, FY2021: 36.9M Gross profit, FY2021: 17.6M Net income, FY2021: -9.8M Revenue, FY2022: 41.4M Gross profit, FY2022: 17.5M Net income, FY2022: -47.5M Revenue, FY2023: 36.7M Gross profit, FY2023: 10.3M Net income, FY2023: -36.8M Revenue, FY2024: 37.7M Gross profit, FY2024: 7.2M Net income, FY2024: -26.7M Revenue, FY2025: 40.5M Gross profit, FY2025: 13.4M Net income, FY2025: -17.3M FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $31.3M $36.9M $41.4M $36.7M $37.7M $40.5M
Gross profit — $17.8M $17.6M $17.5M $10.3M $7.2M $13.4M
Net income — $3.6M -$9.8M -$47.5M -$36.8M -$26.7M -$17.3M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Code of ethics change The code of ethics changed, or somebody was excused from part of it. Item 5.05
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Shareholder vote Item 5.07
  • Results announced Item 2.02
  • Annual report filed Form 10-K

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2835

TickerCompanyMarket capP/ERevenue growth
IDXX IDEXX LABORATORIES INC /DE $44.15B 42.8x 10.4%
LNTH Lantheus Holdings, Inc. $6.51B 29.3x 0.5%
NEOG NEOGEN CORP $2.66B — -2.7%
CLDX Celldex Therapeutics, Inc. $2.30B — -78.0%
NTLA Intellia Therapeutics, Inc. $1.57B — 16.9%
QDEL QuidelOrtho Corp $941.5M — -1.9%
ACHV ACHIEVE LIFE SCIENCES, INC. $667.8M — —
MYGN MYRIAD GENETICS INC $556.7M — -1.6%